NDAORAL-21TABLET
Approved
Jul 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OVCON-35 (ethinyl estradiol; norethindrone) by AbbVie. Approved for pregnancy. First approved in 1978.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OVCON-35 is a combination oral contraceptive containing ethinyl estradiol and norethindrone, indicated for pregnancy prevention. It is a small-molecule hormonal product administered as a 21-day tablet regimen that works by suppressing ovulation through estrogen and progestin activity. This product represents a foundational contraceptive option in the hormonal birth control market.
LOE Approaching
As a legacy product approaching loss of exclusivity, OVCON-35 faces declining revenue and likely reduced brand team investment; career growth on this product will be limited unless repositioning strategies are pursued.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
OVCON-35 presents limited career growth opportunities as a legacy product in late-stage lifecycle managed by AbbVie. Roles on this product are primarily focused on revenue protection, customer retention, and managed decline rather than growth or innovation initiatives.
Brand Manager
Worked on OVCON-35 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.